Clinical outcomes after percutaneous coronary intervention involving very long segments of drug-eluting stent implantation: Single-center experience

Journal of Invasive Cardiology

Volumn 21, Issue 2, 2009, Pages 46-50

  Andron, Mohammed ^a   Ramsdale, David R ^a   Rao, Archana ^a   Ramsdale, Kathryn A ^a   Albouaini, Khaled ^a  

^a LIVERPOOL HEART AND CHEST HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

'TAXUS'; ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; COSTAR; CREATINE KINASE MB; CYPHER; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOGRAPHY; ANTICOAGULANT THERAPY; AORTA DISSECTION; AORTA ROOT; ARTICLE; BARE METAL STENT; CAUSE OF DEATH; COHORT ANALYSIS; CORONARY ARTERY DISEASE; CREATINE KINASE BLOOD LEVEL; DRUG ELUTING STENT; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; IMPLANTATION; IN-STENT RESTENOSIS; KELOID; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; Q WAVE; RETROPERITONEAL HEMORRHAGE; SAPHENOUS VEIN GRAFT; STENT THROMBOSIS; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; DRUG-ELUTING STENTS; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; TIME FACTORS; TREATMENT OUTCOME;

EID: 60149110327     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Grube E, Silber S, Hauptman KE, et al. TAXUS I: Six- and twelve-month results from a randomized, double-blind trial on a slow release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42.
2. Colombo A, Drzewiecki J, Banning A, et al. TAXUS II Study Group. Randomized study to assess the effectiveness of slow and moderate-release polymer-based paclitaxel-eluting stent for coronary artery lesions. Circulation 2003;108:788-794.
3. Stone GW, Ellis SG, Cox DA, et al. TAXUS IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
4. Morice M-C, Serruys PW, Sousa JE, et al. RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
5. Moses JW, Leon MB, Popma JJ, et al. SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
6. Stone GW, Ellis SG, Cannon L, et al. TAXUS V Investigators. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: A randomized controlled trial. JAMA 2005;294:1215-1223.
7. Dawkins KD, Grube E, Guagliumi G, et al. TAXUS VI Investigators. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: Support for the use of drug-eluting stents in contemporary clinical practice. Circulation 2005;112:3306-3313.
8. Rao SV, Shaw RE, Brindis RG, et al. American College of Cardiology National Cardiovascular Data Registry. On- versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry [NCDR]). Am J Cardiol 2006;97:1478-1481.
9. Büttner HJ, Neumann FJ. Peeling-off labels: Mounting evidence for benefit of drug-eluting stents with off-label use. J Am Coll Cardiol 2007;50:2037-2038.
10. Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-1029.
11. Marroquin OC, Selzer F, Mulukutla SR, et al. A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med 2008;358:342-352.
12. Schampaert E, Cohen EA, Schlüter M, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43:1110-1115.
13. Degertekin M, Arampatzis CA, Lemos PA, et al. Very long sirolimus-eluting stent implantation for de novo coronary lesions. Am J Cardiol 2004;93:826-829.
14. Grube E, Dawkins KD, Guagliumi G, et al. TAXUS VI 2-year follow-up: Randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions. Eur Heart J 2007;28:2578-2582.
15. Chieffo A, Bonizzoni E, Orlic D, et al. Intraprocedural stent thrombosis during implantation of sirolimus-eluting stents. Circulation 2004;109:2732-2736.
16. de la Torre-Hernández JM, Alfonso F, Hernández F, et al. Drug-eluting stent thrombosis: Results from the multicenter Spanish registry ESTROFA (Estudio ESpañol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol 2008;51:986-990.
17. Roy P, Steinberg DH, Sushinsky SJ, et al. The potential clinical utility of intravascular ultrasound guidance in patients undergoing percutaneous coronary intervention with drug-eluting stents. Eur Heart J 2008;29:1851-1857.